Diabetes treatment is changing quickly. Headlines promise “skinny shots,” surgery-level weight loss and pills that may replace injections. The useful question is not which medicine is newest, but which option fits a person’s diabetes, heart and kidney health, weight goals, side-effect risk, access and budget.
This article maps the landscape as of July 21, 2026. Approvals and availability differ by country and can change. It is not a recommendation to start, stop or switch treatment.
The big story: GLP-1 and dual-agonist medicines
GLP-1 receptor agonists, including semaglutide, mimic a gut hormone involved in insulin release, appetite and digestion. Depending on the particular medicine and indication, they can lower HbA1c, support weight loss and provide cardiovascular or kidney benefits for selected patients.
Tirzepatide acts on both GIP and GLP-1 receptors. It is used for Type 2 diabetes in approved markets and has produced substantial glucose and weight reductions in trials. In the 72-week SURMOUNT-5 trial, tirzepatide produced greater average weight loss than semaglutide—but the participants were adults with obesity without diabetes. That result should not be presented as a direct head-to-head diabetes-treatment result.
These are prescription medicines, not casual weight-loss products. Common adverse effects include nausea, vomiting, diarrhoea and constipation; less common risks and contraindications require individual medical review. Medicines obtained through social media or informal sellers may be counterfeit, improperly stored or unsuitable.
The India reality: access, cost and hype
Availability, approved indications, brands and prices can change quickly in India. Confirm the current status through India’s official regulator, a licensed pharmacy and the prescribing clinician rather than relying on a social-media post or an old price quoted online.
Cost matters because diabetes care is long term. The relevant comparison is not only the monthly price: it also includes expected benefit, side effects, monitoring, other health conditions, insurance or reimbursement, and whether treatment can be sustained. A medicine that cannot be used consistently is not automatically a better choice because it is newer.
The quieter change: SGLT2 inhibitors
SGLT2 inhibitors, such as empagliflozin and dapagliflozin, lower glucose by increasing glucose excretion in urine. Their importance now reaches beyond HbA1c: evidence supports heart-failure and chronic-kidney-disease benefits in appropriate patients, including some people without diabetes.
They also have specific risks, including genital infections, dehydration and rare diabetic ketoacidosis, so sick-day advice and individual kidney-function assessment matter. The right choice depends on the patient’s clinical profile, not on a simple ranking of “old” versus “new.”
Insulin, made simpler
Insulin icodec, sold as Awiqli in some markets, is a once-weekly basal insulin. The European Medicines Agency authorised it in the European Union in 2024. It may reduce injection burden for suitable patients, but weekly dosing brings different safety and dose-adjustment considerations. Approval and availability in India should be checked locally.
What is approved, and what is still emerging?
Oral semaglutide: tablet semaglutide already exists for Type 2 diabetes, and the US FDA approved a higher-dose oral Wegovy tablet for chronic weight management in late 2025. Indications and availability vary by country.
Orforglipron: this oral GLP-1 medicine is no longer accurately described simply as “in trials.” The US FDA approved Foundayo (orforglipron) for chronic weight management on April 1, 2026. That US decision does not establish approval or availability in India, and it is not the same as a diabetes indication.
Retatrutide and combinations: triple-agonist retatrutide and combinations such as CagriSema remain areas of active research. Promising trial results do not make an investigational product available or appropriate for use today.
What this means for someone with Type 2 diabetes
There is no universal medication ladder. Current guidance emphasises person-centred treatment. Metformin remains an effective, well-established and affordable option for many people, but a clinician may prioritise an SGLT2 inhibitor or GLP-1–based medicine—sometimes independently of metformin or current HbA1c—when cardiovascular disease, heart failure, chronic kidney disease or weight management is central.
A useful appointment focuses on five questions: What is the main treatment goal? What benefit is expected for this person? What side effects or contraindications matter? What monitoring is needed? Can the plan be accessed and sustained? Lifestyle support, sleep, movement, nutrition and stopping tobacco remain important alongside—not in competition with—appropriate medication.
If you smoke and have diabetes
Smoking adds cardiovascular and microvascular risk to diabetes. Quitting is the most effective tobacco-related step. See our diabetes and smoking guide, diabetic heart guide, and quitting support.
Where Smokesafer Gold fits in
For adult cigarette smokers who are not yet able to quit, Smokesafer Gold is a cigarette-filter harm-reduction accessory. It does not diagnose, prevent or treat diabetes and is not a medical device or cessation therapy. No filter makes smoking safe.
Gold-specific reductions were reported under independent laboratory test conditions; results may vary with smoking behaviour. View independent lab data.
Medical disclaimer: This article is for general education and is not medical advice. Drug approvals, indications, supply and prices vary by country and change over time. Never start, stop, switch or change the dose of diabetes medicine based on an article. Use prescription medicines only through legitimate medical and pharmacy channels, and seek urgent care for severe or rapidly worsening symptoms.
Sources
American Diabetes Association: Standards of Care in Diabetes—2026, pharmacologic approaches; SURMOUNT-5: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity; European Medicines Agency: Awiqli; US FDA: orforglipron approval; and US FDA: oral Wegovy prescribing information. Accessed July 21, 2026.